Pfizer-BioNTech Evaluating Third COVID-19 Vaccine Dose for Variants
The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.
Related Articles
New Genomic Study Reveals Hidden Pathways of C difficile Transmission in Hospitals
Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies
Clinical Insights on HIV-Associated Visceral Fat Following FDA Approval of Tesamorelin F8
David Wohl, MD, discusses the complexities of diagnosing and the importance of managing ectopic fat in HIV patients.
“Golden Hour” to Start Antibiotic in Suspected Sepsis
Patients with suspected sepsis in the emergency department are twice as likely to survive at 28 days when antibiotics are started within 1 hour.
Conference on Retroviruses and Opportunistic Infections (CROI)
Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.
CDC: Hospitals Experiencing Inconsistent Declines in Resistant Infections
A long-term study conducted by the Centers for Disease Control and Prevention (CDC) shows early success in the reduction of such infections followed by an…
Zoonotic Hookworm Infection and Cutaneous Larva Migrans
Amanda Truong, MD, PhD, provides her perspective on diagnosis, treatment, and environmental factors, considering her involvement in a recent human case.
Phase 2 Study Shows Efficacy of Six-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIV-1
Onyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.
Fear, Misconceptions Discourage International Hepatitis B and C Testing
Despite a large number of new infections globally, an international survey shows real reservations by people to get screened and limited knowledge about the risks,…
Bictegravir vs Darunavir in Advanced HIV: Results from the LAPTOP Trial
Georg Behrens, MD, PhD, highlights superior virological suppression and immune recovery with bictegravir-based therapy in therapy-naïve individuals with advanced HIV disease.